RxDoctor Payments Data

Ellsworth Grant, MD

Hematology & Oncology · Los Angeles, CANPI 1043233760

Payments from drug & device makers

$22,206in general payments, 2019–2025

Across 929 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Pfizer$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Johnson & Johnson$1K
  • AstraZeneca$942
  • Genentech USA, Inc.$880
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$18,78885%
  • Education$7373%
  • Other$2,68112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis111$4,304
Pfizer89$1,559
E.r. Squibb & Sons, L.L.C.101$1,471
Johnson & Johnson(2 entities)47$1,181
AstraZeneca(2 entities)43$942
Genentech USA, Inc.42$880
Merck35$872
Bristol Myers Squibb42$784
Incyte Corporation32$780
Astellas Pharma US Inc23$697
Exelixis Inc.24$682
Amgen27$635
Takeda Pharmaceuticals U.S.A., Inc.21$582
Sanofi25$560
Eisai Inc.20$430
Daiichi Sankyo Inc.18$383
Pharmacyclics LLC, An Abbvie Company12$351
Karyopharm Therapeutics Inc.12$344
Gilead12$288
GSK12$283
Bayer13$277
Pharmaessentia USA Corporation10$260
Boehringer Ingelheim11$247
Blueprint Medicines Corporation8$206
AbbVie8$183
Emmaus Medical, Inc.8$172
Secura Bio, Inc.6$169
Progenics Pharmaceuticals, Inc.7$155
Global Blood Therapeutics, Inc.8$150
EMD Serono, Inc.7$149
Mirati Therapeutics, Inc.6$145
Chiesi USA, Inc.7$128
Coherus Oncology, Inc.6$123
Taiho Oncology, Inc.5$118
Seagen Inc.5$115
Puma Biotechnology, Inc.4$101
Sanofi-aventis U.S. LLC1$87
Acrotech Biopharma Inc.2$85
Alnylam Pharmaceuticals Inc.3$83
ADC Therapeutics America, Inc.3$78
Sun Pharmaceutical Industries Inc.3$67
Tolmar Pharmaceuticals, Inc.3$65
EUSA Pharma (US) LLC4$64
Azurity Pharmaceuticals, Inc.3$63
Teva Pharmaceuticals USA, Inc.2$57
Foundation Medicine, Inc.2$56
Organon3$54
Morphosys, US Inc.3$50
Array Biopharma Inc2$44
Agios Pharmaceuticals, Inc.2$43
Pharmacosmos Therapeutics Inc.2$42
Lilly USA, LLC2$40
Beigene USA, Inc.1$32
Genmab U.S., Inc.1$32
Adaptive Biotechnologies Corporation1$30
Dendreon Pharmaceuticals LLC1$28
Immunogen, Inc.1$28
Stemline Therapeutics Inc.1$28
Amneal Pharmaceuticals LLC1$28
Jazz Pharmaceuticals Inc.1$27

How this compares

$22,206 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$663,628
Medicare patients
124
Services billed
26,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$275,180
TrazimeraTrastuzumab-Qyyp20$96,193
Abiraterone Acetate14$34,204
ZirabevBevacizumab-Bvzr12$34,161
EliquisApixaban43$25,983
ActemraTocilizumab12$16,911
Oxycodone Hcl53$2,017
Aprepitant12$1,893
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$1,620
Letrozole31$664
Hydromorphone Hcl30$515
Anastrozole45$444
Albuterol Sulfate HfaAlbuterol Sulfate14$308
Gabapentin34$195
Ondansetron Hcl17$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$697$275,18020 claims
PfizerTrazimera, Zirabev, Eliquis$1,559$156,33675 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →